Multibagger stock: This pharma company gave 650% return in just 6 months, did you buy?

Multibagger stock: Some stocks have managed to make it to the multibagger stock list of the year 2021 amidst new records being made daily in the stock market. ANG LifeSciences is one such stock. This pharma sector company has given a return of about 650% to the shareholders in the last 6 months. In the last 6 months, the price of its shares has jumped by 85.50 paise to 642.10 per share.

On Friday, profit booking was seen in the shares of this multibagger stock, due to which it fell about 5 percent and closed at Rs 642.10. It also touched its all-time high of Rs 744.70 during this week’s trading, though it could not maintain its momentum after that.

Get 5000 rupees monthly pension through this government scheme, know can you apply

However, despite this, the stock has given a return of around 22% in the last one month. A month ago, the price of its shares was Rs 527 per share. Similarly, in the last six months, its shares have jumped from Rs 85.50 to Rs 642.50 and the shareholders got a return of about 650% during this period.

If an investor had invested Rs 1 lakh in this multibagger stock a month ago, his amount would have become Rs 1.22 lakh by now. Similarly, if an investor had invested Rs 1 lakh in it three months back, his amount would have increased nearly three and a half times to Rs 3.56 lakh.

On the other hand, if an investor would have invested Rs 1 lakh in it 6 months ago, then his amount would have increased to Rs 7.50 lakh today.

Biocon Biologics announced, will give 15% stake to Serum Institute of Life Sciences

How will the stock move going forward?
Several brokerage firms have given buy rating to the stock of ANG Life Sciences. Sumeet Bagadia, Executive Director, Choice Broking said, “This pharma stock has strong support at Rs 600 to Rs 625. It can be bought at current market price with a target price of Rs 750 to Rs 800. Also go for this. Stop loss should be placed at Rs 600.

Facebook us for social media updates ( and Twitter (.) to follow.


Add a Comment

Your email address will not be published. Required fields are marked *